Gynecologic Cancers | Topics

Tiffany Sia, MD, Provides Rationale for Exploring Interventions for Oligoprogressive Disease in Gynecologic Malignancies Treated With ICI
September 30, 2022

At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.

Nivolumab ± Ipilimumab Yields Meaningful, Durable Responses in Recurrent or Metastatic Cervical Cancer
September 28, 2022

The 24-month follow-up of the phase 1/2 CheckMate 358 trial found nivolumab with or without ipilimumab yielded clinically meaningful, long-lasting responses in patients with recurrent or metastatic cervical cancer.

Local Treatment Choice for Cervical Intraepithelial Neoplasia and Stage IA1 Cervical Cancer Appears to Influence Efficacy, Risk of Preterm Birth
August 19, 2022

In a population of patients with cervical intraepithelial neoplasia and stage IA1 cervical cancer, certain local treatments, such as radical excision and ablation, were associated with treatment outcomes and risk of preterm birth.

Clinical Unmasking May Cause Increased Rates of High-Grade Cervical Neoplasia From Non–Vaccine Preventable HPV
August 01, 2022

Investigators reported that vaccinated patients had a higher rate of grade 2/3 cervical neoplasia due to non–vaccine preventable human papillomavirus compared with unvaccinated patients, an event commonly termed clinical unmasking.

Apatinib Plus Pegylated Liposomal Doxorubicin Yields Significant Efficacy in Advanced Ovarian Cancer
July 11, 2022

Results from the phase 2 APPROVE trial showed apatinib plus pegylated liposomal doxorubicin improved efficacy and safety compared with pegylated liposomal doxorubicin alone for patients with platinum-resistant recurrent ovarian cancer.

OS Not Improved, Modest PFS Benefit Noted Following Chemo Maintenance in Newly Diagnosed Advanced Ovarian Cancer
July 08, 2022

Patients with advanced newly diagnosed ovarian, tubal, or peritoneal cancer did not derive further survival benefit from maintenance chemotherapy, although a modest improvement in progression-free survival was observed compared with surveillance.

Association Identified Between Malnutrition and Post-Operative Outcomes in Gynecologic Cancer
June 20, 2022

Nutritional markers such as body mass index, weight loss, and albumin should be assessed to identify pre-operative malnutrition in patients with gynecologic cancers.

No Difference in Survival Observed in Uterine Carcinosarcoma Following SLN Biopsy vs Systemic LND
June 15, 2022

Patients with uterine carcinosarcoma who underwent sentinel lymph node biopsy or systemic lymph node dissection did not experience a difference in progression-free survival or overall survival.

Cancer Vaccine VB10.16 Plus Atezolizumab Yields Promising Responses in HPV16+ Advanced Cervical Cancer
May 10, 2022

Patients with advanced human papillomavirus 16–positive cervical cancer appear to benefit from treatment with VB10.16 and atezolizumab.

Stereotactic Hypofractionated Radiation Therapy Well Tolerated in Uterine Cancer
May 09, 2022

The phase 1/2 SPARTACUS trial assessed the use of stereotactic hypofractionated radiation therapy in patients with uterine cancer; the treatment appeared to be well tolerated.